First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma

Abstract

BACKGROUNDPatients with advanced cervical carcinoma are treated routinely with radiotherapy and cisplatin‐containing chemotherapy. It has been shown that hyperthermia can improve the results of both radiotherapy and cisplatin. In the current study, the feasibility and efficacy of the combination of all three modalities was studied in previously untreated patients with cervical carcinoma.METHODSPatients with advanced cervical carcinoma were registered prospectively in the U.S., Norway, and the Netherlands. External‐beam radiotherapy and brachytherapy were administered for a biologically effective dose ≥ 86.7 gray. At least 4 courses of weekly cisplatin (40 mg/m2) and 4 sessions of weekly locoregional hyperthermia were added to radiotherapy.RESULTSSixty‐eight patients with a median age of 45 years were enrolled. Full‐dose radiotherapy was delivered to all patients according to plan. At least 4 courses of chemotherapy were received by 97% of patients, and at least 4 courses of hyperthermia treatment were received by 93% of patients. Toxicity was fully comparable to that described for chemoradiotherapy alone, and the median total treatment time was 45 days. Complete remission was achieved by 61 patients (90%). After a median follow‐up of 538 days, 74% of patients remained alive without signs of recurrence, and the overall survival rate was 84%.CONCLUSIONSThe combination of full‐dose radiotherapy, chemotherapy, and hyperthermia was feasible and effective in a multicenter international setting among patients with advanced cervical carcinoma. A Phase III study comparing this novel triplet with standard chemoradiation, designed to show at least a 15% improvement in overall survival, has been launched. Cancer 2005. © 2005 American Cancer Society.

Targeting the Heat Shock Factor 1 by RNA Interference: A Potent Tool to Enhance Hyperthermochemotherapy Efficacy in Cervical Cancer

“…The advanced capability to deploy heat with more sophisticated modalities has led to a resurgence in interest in hyperthermia for cervical cancer especially in combination with either radiation or cisplatin (13,39). Recently, the combination of radiotherapy with hyperthermochemotherapy in a triple-modality treatment for advanced cervical cancer has been shown to increase both response rate and survival time in a phase II study and is currently in phase III trial (40,41). The results described herein show that a further improvement in sensitivity to hyperthermochemotherapy may be obtained by targeting HSF1.…”

A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer

“…Westermann et al [28] analysed prospective survival data for a combination of CRT and HT in 68 patients with stage IIB-IVA CC in 2005. They also reported the same patients' long-term survival rates in 2012 [13].…”

NIR responsive liposomal system for rapid release of drugs in cancer therapy

“…acridine orange (aO) staining AO fluorescent dyes were further used to assess the disruption of lysosomal membranes in MCF-7 cells. 15 MCF-7 cells were seeded at a density of 2×10 5 cells/well at a 12-well plate and then incubated overnight at 37°C with 5% CO 2 . After treated with Cypate/DOX-L and Cypate/DOX-BTSL at the Cypate concentrations of 0.5, 1, and 2 μg/mL for 4 h, the cells were exposed to photoirradiation for 10 min at 780 nm, 2.8 W/cm 2 .…”

“…[1][2][3][4] Photothermal therapy (PTT) has been considered as a noninvasive method of cancer therapy, which uses photothermal agents to generate heat under photoirradiation without injuring healthy tissues. 5,6 Although PTT is highly effective in inhibiting tumor growth, it remains a major challenge to achieve tumor eradication without tumor regrowth. A combination therapy of PTT and chemotherapy has been considered as a promising strategy to improve therapeutic efficiency and minimize side effects.…”